Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020, specifically reporting a transaction notification dated May 7, 2020. The filing serves as a disclosure of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a transaction notification regarding the sale of securities.
| Metric | Value |
|---|---|
| Transaction Type | Sale of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $42.11 |
| Transaction Volume | 1,666.387 ADSs |
| Transaction Date | May 5, 2020 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the reduction in holdings of the specific PDMR involved in the transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies related to the company's business operations. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Mr. N Hirons, SVP, Global Ethics & Compliance.
- Transaction Nature: This was an initial notification of a sale of 1,666.387 ADSs.
- Market Price: The shares were sold at $42.11 per ADS on the NYSE.
- Scope: This document does not reflect the company's overall financial health or strategic direction.